CA2236339A1 - Procede de criblage par fluorescence destine a l'identification de ligands - Google Patents

Procede de criblage par fluorescence destine a l'identification de ligands Download PDF

Info

Publication number
CA2236339A1
CA2236339A1 CA002236339A CA2236339A CA2236339A1 CA 2236339 A1 CA2236339 A1 CA 2236339A1 CA 002236339 A CA002236339 A CA 002236339A CA 2236339 A CA2236339 A CA 2236339A CA 2236339 A1 CA2236339 A1 CA 2236339A1
Authority
CA
Canada
Prior art keywords
target protein
test
ligand
protein
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002236339A
Other languages
English (en)
Inventor
Robert T. Sauer
Andrew Pakula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anadys Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2236339A1 publication Critical patent/CA2236339A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau procédé d'évaluation de l'efficacité pharmaceutique de composés chimiques. Le procédé décrit permet d'identifier des ligands ayant une valeur thérapeutique en les mettant en présence de protéines cibles et en déterminant leur capacité à empêcher le dépliement partiel de la protéine cible, ceci en mesurant l'émission de la fluorescence d'une sonde sensible à la conformation. Ce procédé diffère sensiblement des procédés connus d'évaluation de nouveaux composés pharmaceutiques en ce que la fonction biochimique de la protéine cible n'a pas besoin d'être connue et en ce que l'existence de ligands connus de la protéine cible n'est pas une nécessité.
CA002236339A 1995-12-07 1996-12-06 Procede de criblage par fluorescence destine a l'identification de ligands Abandoned CA2236339A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US834695P 1995-12-07 1995-12-07
US60/008,346 1995-12-07

Publications (1)

Publication Number Publication Date
CA2236339A1 true CA2236339A1 (fr) 1997-06-12

Family

ID=21731102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002236339A Abandoned CA2236339A1 (fr) 1995-12-07 1996-12-06 Procede de criblage par fluorescence destine a l'identification de ligands

Country Status (5)

Country Link
EP (1) EP0865502A4 (fr)
JP (1) JP2000502440A (fr)
CA (1) CA2236339A1 (fr)
DE (1) DE865502T1 (fr)
WO (1) WO1997020952A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2184195C (fr) 1995-10-25 2002-04-16 Andrew Pakula Methode d'analyse pour la caracterisation de ligands de proteines cibles
CA2253587C (fr) 1996-05-09 2008-01-29 3-Dimensional Pharmaceuticals, Inc. Procede d'analyse et appareil a changement thermique et a microplaque pour l'optimisation de la mise au point de ligands et de la chimie des proteines a variables multiples
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
WO1998020437A2 (fr) 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. Systeme, procede et programme produit informatique pour identifier des composes chimiques presentant des proprietes desirees
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
US6261842B1 (en) 1997-10-23 2001-07-17 Wisconsin Alumni Research Foundation Microorganism genomics, compositions and methods related thereto
WO1999024050A1 (fr) * 1997-11-12 1999-05-20 3-Dimensional Pharmaceuticals, Inc. Procede a haut rendement permettant de classer fonctionnellement des proteines identifiees par une methode des genomes
US20020010550A1 (en) 1998-09-14 2002-01-24 George M. Grass Pharmacokinetic-based drug design tool and method
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
JP2002535989A (ja) 1999-02-04 2002-10-29 アナディーズ・ファーマスーティカルズ，インコーポレイテッド カンジダ・アルビカンスｓｒｂ‐７
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
US6582907B1 (en) 1999-12-09 2003-06-24 Pharmacia & Upjohn Company Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions
US6376180B1 (en) * 1999-12-09 2002-04-23 Pharmacia & Upjohn Company Methods of identifying compounds that bind to target species under isothermal denaturing conditions
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
AU2001241800A1 (en) 2000-02-29 2001-09-12 3-Dimensional Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
WO2001071624A1 (fr) 2000-03-22 2001-09-27 3-Dimensional Pharmaceuticals, Inc. Systeme, procede et progiciel pour la representation de relations entre objets dans un espace multidimensionnel
WO2001075790A2 (fr) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Procede, systeme, et produit informatique permettant de representer un objet dans un espace a plusieurs dimensions
US7054757B2 (en) 2001-01-29 2006-05-30 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Method, system, and computer program product for analyzing combinatorial libraries
WO2002103321A2 (fr) * 2001-06-14 2002-12-27 Anadys Pharmaceuticals, Inc. Procedes de criblage de ligands de molecules cibles
EP1637885A1 (fr) * 2004-09-16 2006-03-22 Vivalis Méthode de criblage en employant des peptides sensibles à la conformation de protéines
GB0421285D0 (en) 2004-09-24 2004-10-27 Univ Nottingham Improvements in high content screening
US8158340B2 (en) 2005-12-28 2012-04-17 Corning Incorporated Methods for detecting conformational changes in bioentities
EP3254113A4 (fr) 2015-02-05 2018-06-27 Promega Corporation Analyses à variation thermique fondées sur la luciférase
GB202118173D0 (en) * 2021-12-15 2022-01-26 Medicines Discovery Catpult Ltd Protein stability assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231755B2 (fr) * 1973-01-08 1977-08-17
US5200504A (en) * 1990-10-02 1993-04-06 The Scripps Research Institute Metallopeptides having stabilized secondary structures
CA2115900A1 (fr) * 1993-02-22 1994-08-23 Gerald W. Becker Cribles pharmaceutiques et anticorps

Also Published As

Publication number Publication date
JP2000502440A (ja) 2000-02-29
EP0865502A1 (fr) 1998-09-23
DE865502T1 (de) 1999-08-19
WO1997020952A1 (fr) 1997-06-12
EP0865502A4 (fr) 2000-08-16

Similar Documents

Publication Publication Date Title
CA2236339A1 (fr) Procede de criblage par fluorescence destine a l'identification de ligands
US5679582A (en) Screening method for identifying ligands for target proteins
US5585277A (en) Screening method for identifying ligands for target proteins
WO1997020952A9 (fr) Procede de criblage par fluorescence destine a l'identification de ligands
EP0770876B1 (fr) Méthode de screening pour l'identification de ligands des protéines cibles
US5976813A (en) Continuous format high throughput screening
EP2660601B1 (fr) Procédés de détection d'interactions moléculaires
US7771940B2 (en) Methods of detecting a plurality of sequence specific DNA binding proteins with oligonucleotide detection duplexes
WO2002103321A2 (fr) Procedes de criblage de ligands de molecules cibles
EP1399582A1 (fr) Procede permettant de detecter une maladie renale par profilage des proteines
MXPA96004183A (en) Method of examination to identify paraprotein ligands objet
CN101460853A (zh) 基于测定γ-分泌酶Aβ切割产物的比值诊断阿尔兹海默病的方法
US6376180B1 (en) Methods of identifying compounds that bind to target species under isothermal denaturing conditions
US20040018504A1 (en) Method for extracting quantitative information relating to interactions between cellular components
EP0883810A1 (fr) DETECTION DE COMPOSES DE TYPE DIOXINE PAR DETECTION DU COMPLEXE RECEPTEUR Ah TRANSFORME/ARNT
US20040191835A1 (en) Screening method for identifying ligands for target proteins
EP1235925B1 (fr) Dosage d'alimentation pour identifier les composes nematicides
MXPA98004456A (en) Method of analysis based on fluorescence, to identify ligan
JP3768165B2 (ja) 抗カルパスタチン抗体の測定法及び測定キット
JP2004502433A (ja) 興味のある輸送タンパク質の活性を測定する簡易な定量蛍光アッセイ方法
Mayer Cell‐free reconstitution of microautophagy in yeast
US20030129634A1 (en) General screening method for ligand-protein interactions
WO2002066982A1 (fr) Analyse de modifications et de demodifications de proteines avec des proteines apparentees a l'ubiquitine par fret (transfert d'energie de resonance par fluorescence)

Legal Events

Date Code Title Description
FZDE Dead